{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"99.6","value":"88.9"},{"groupId":"OG001","spread":"203.5","value":"28.6"},{"groupId":"OG002","spread":"159.6","value":"8.10"},{"groupId":"OG003","spread":"130.9","value":"38.2"},{"groupId":"OG004","spread":"869.4","value":"11.8"},{"groupId":"OG005","spread":"429.6","value":"5.36"},{"groupId":"OG006","spread":"137.4","value":"42.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"6"},{"groupId":"OG006","value":"21"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on dabrafenib plasma concentrations by using non-compartmental methods. Ctrough is defined as the observed plasma concentration just prior to the beginning of, or at the end, of a dosing interval.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 50% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (2.63 mg/kg/day for \\<12 years old subjects and 2.25 mg/kg/day for ≥12 years old subjects)","id":"OG000","title":"Part C - TMT 0.025 mg/kg/Day + 50% DRB RP2D"},{"description":"Participants treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"OG001","title":"Part C - TMT 0.025 mg/kg/Day + 100% DRB RP2D"},{"description":"Participants under 6 years of age treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)","id":"OG002","title":"Part C - TMT 0.032 mg/kg/Day + 100% DRB RP2D"},{"description":"Participants with low grade glioma (LGG) treated with a combination therapy of trametinib (0.032 mg/kg/day for \\< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"OG003","title":"Part D - LGG"},{"description":"Participants with Langerhans cell histiocytosis (LCH) treated with a combination therapy of trametinib (0.032 mg/kg/day for \\< 6 years old subjects and 0.025 mg/kg/day for ≥ 6 years old subjects) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"OG004","title":"Part D - LCH"},{"description":"Participants under 6 years of age (all tumor types in Part D) treated with a combination therapy of trametinib (0.032 mg/kg/day) with 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day)","id":"OG005","title":"Part D - All Tumor Types TMT 0.032 mg/kg/Day + 100% DRB RP2D"},{"description":"Participants (all tumor types in Part D) treated with a combination therapy of trametinib (0.025 mg/kg/day) plus 100% of the recommended phase II dose (RP2D) of dabrafenib monotherapy (5.25 mg/kg/day for \\<12 years old subjects and 4.5 mg/kg/day for ≥12 years old subjects)","id":"OG006","title":"Part D - All Tumor Types TMT 0.025 mg/kg/Day + 100% DRB RP2D"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"All subjects who received at least one dose of dabrafenib in Part C and D and provided an evaluable PK profile with a value for the outcome measure","reportingStatus":"POSTED","timeFrame":"pre dose on Cycle 1 Day 15. The duration of 1 cycle was 28 days.","title":"Trough Concentration (Ctrough) of Dabrafenib When Administered in Combination With Trametinib","type":"SECONDARY","unitOfMeasure":"ng/mL"}